WSTHealthcare · Medical Instruments & SuppliesThe 16 Wall Street analysts covering West Pharmaceutical Services, Inc. hold a median 12-month price target of $410 — +18.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 93 of 100 as at 17 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores West Pharmaceutical Services, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (97): Analysts have, on balance, been raising their forecasts.
Accruals (38): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (9): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on WST, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +18.3% from it.
Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 3 Aug 2026 | Citigroup | Maintains | Buy | $400 → $412 |
| 27 July 2026 | Evercore ISI Group | Maintains | Outperform | $410 → $425 |
| 13 July 2026 | BNP Paribas | Initiates | Outperform | $447 |
| 13 July 2026 | BNP Paribas | Initiates | Outperform | — |
| 9 July 2026 | Morgan Stanley | Maintains | Equal-Weight | $325 → $365 |
| 9 July 2026 | Morgan Stanley | Maintains | Equal-Weight | — |
| 6 July 2026 | Evercore ISI Group | Maintains | Outperform | $390 → $410 |
| 6 July 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 2 July 2026 | Keybanc | Maintains | Overweight | — |
| 9 June 2026 | Barclays | Upgrade | Overweight | — |
| 2 June 2026 | Stephens & Co. | Reiterates | Overweight | — |
| 2 June 2026 | Wolfe Research | Assumes | Outperform | — |
| 29 May 2026 | Morgan Stanley | Maintains | Equal-Weight | — |
| 27 Apr 2026 | Barclays | Maintains | Equal-Weight | — |
| 14 Apr 2026 | Barclays | Maintains | Equal-Weight | — |
| 13 Feb 2026 | Barclays | Maintains | Equal-Weight | — |
| 3 Feb 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 2 Dec 2025 | Morgan Stanley | Initiates | Equal-Weight | — |
| 29 Oct 2025 | TD Cowen | Initiates | Buy | — |
| 27 Oct 2025 | Barclays | Maintains | Equal-Weight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. WST appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 17% of US stocks
Cheaper than 18% of US stocks
Cheaper than 13% of US stocks
Cheaper than 11% of US stocks
Higher than 61% of US stocks
Higher than 55% of US stocks
Higher than 47% of US stocks
Higher than 82% of US stocks
Higher than 80% of US stocks
Higher than 80% of US stocks
Higher than 94% of US stocks
Higher than 4% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own West Pharmaceutical Services, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
West Pharmaceutical Services stock has surged 38.1% since the end of March. The rally is attributed to higher demand for high-value products (HVP), growth related to GLP-1 products, and productivity gains.
Why it matters — For WST watchers, this highlights the key demand drivers behind the company's recent stock performance and operational momentum.
Zacks Investment Research upgraded West Pharmaceutical (WST) to a Zacks Rank #2 (Buy), citing growing optimism about the company's earnings prospects.
Why it matters — An upgrade from Zacks signals increasing confidence in WST's near-term earnings potential, which could draw more attention from momentum-oriented investors.
Zacks Research discusses whether to buy WST given that its faster HVP growth, wider margins and stronger earnings outlook support the bull case, while cautioning that its premium valuation leaves less room for error.
Why it matters — WST watchers would care because the report weighs the company's growth and profitability strengths against the risk that a premium valuation reduces its margin for error.
West Pharmaceutical reported a Q2 earnings beat, with faster high-value products (HVP) growth and wider margins that drove a raised 2026 outlook, strengthening its earnings case according to Zacks Investment Research.
Why it matters — A WST watcher would care because the Q2 beat and improved 2026 guidance point to sustained momentum in the company's growth business.
West Pharmaceutical Services shares have risen 15.3% over the past three months, supported by growth in its high-value products (HVP), wider margins, and an improved 2026 outlook.
Why it matters — A WST watcher would care because the stock's recent rally is tied to the company's core HVP growth and a raised forward outlook, though a premium valuation could limit additional upside.
The 16 Wall Street analysts covering West Pharmaceutical Services, Inc. have a median 12-month price target of $410, with estimates ranging from $340 to $459. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 16 analysts covering West Pharmaceutical Services, Inc., 14 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks West Pharmaceutical Services, Inc. 93 out of 100 across roughly 4,600 US stocks as at 17 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 17 Aug 2026, West Pharmaceutical Services, Inc. ranks 93 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (97 of 100).
No one can know that. What the data says: the median 12-month target from 16 analysts implies +18.3% from the last close, and Ticker Nerd's factor model ranks West Pharmaceutical Services, Inc. 93 out of 100 as at 17 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering West Pharmaceutical Services, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for WST are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $340 to $459 over the next 12 months.
West Pharmaceutical Services, Inc. returned +41.2% over the 12 months to 17 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
West Pharmaceutical Services, Inc. is a healthcare manufacturing company that develops and produces containment and delivery solutions for injectable medicines and other pharmaceutical products.
The most recent item we track (Zacks Investment Research, 14 Aug 2026): "WST Stock Surges 38.1% Since March-End: What's Fueling the Rally?". West Pharmaceutical Services stock has surged 38.1% since the end of March. The rally is attributed to higher demand for high-value products (HVP), growth related to GLP-1 products, and productivity gains.
West Pharmaceutical Services, Inc. is a healthcare manufacturing company that develops and produces containment and delivery solutions for injectable medicines and other pharmaceutical products. Its offerings include packaging components, seals, stoppers, plungers, drug delivery systems, and specialized containment technologies used across biologics, vaccines, generic drugs, and other therapies. The company also provides contract manufacturing capabilities for complex devices and automated assembly services, supporting pharmaceutical, diagnostic, and medical device customers. West Pharmaceutical Services plays an important role in the drug development and delivery supply chain by helping protect product integrity, support sterile handling, and enable reliable administration of injectable treatments. Founded in 1923 and headquartered in Exton, Pennsylvania, the company serves customers across global healthcare markets.
CEO Mr. Eric Mark Green · 10,800 employees · United States · https://www.westpharma.com